Furthermore, inhibition of GnRH can decrease the level of testosterone; regulation of PI3K/Akt in decreasing the expression of CYP17A1 avoids the conversion of pregnenolone to DHEA; and downregulation of FSH inhibits the combination between FSH and the FSH receptor to reduce cAMP through the PKA pathway for downregulating aromatase, showing potential therapeutic effects on PCOS. Here, AKT1 is linked to polycystic ovary syndrome.